Weight loss jabs could help cut alcohol consumption, study suggests
It is thought the drugs help curb cravings for alcohol, experts said, although more research is needed.
Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.
The study, led by academics in Ireland and Saudi Arabia, included 262 obese people who had been prescribed liraglutide or semaglutide, which are available under the brand names Saxenda and Wegovy respectively.
They were categorised based on the amount of alcohol they consumed each week prior to starting treatment.
The groups included non-drinkers, rare drinkers who had less than 10 units a week, and regular drinkers, who reported having 10 or more units each week.
Some 188 of the 262 patients were followed up for an average of four months.
Average alcohol consumption fell from 11.3 units a week – about six or seven pints of beer – to 4.3 units a week, or roughly two pints of beer, after four months on the drugs.
Among regular drinkers, intake decreased by 68%, from 23.2 units a week to 7.8 units a week.
Professor Carel le Roux, of University College Dublin, said: 'The exact mechanism of how GLP-1 analogues reduce alcohol intake is still being investigated but it is thought to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are not under conscious control.
'Thus, patients report the effects are 'effortless'.'
The findings, which are being presented at the European Congress on Obesity in Malaga, suggest a 'potential therapeutic role' for weight loss jabs in people who are obese and regularly drink alcohol, researchers said.
However, they stressed larger trials are needed to validate the results.
Prof Le Roux added: 'GLP-1 analogues have been shown treat obesity and reduce the risk of multiple obesity-related complications.
'Now, the beneficial effects beyond obesity, such as on alcohol intake, are being actively studied, with some promising results.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
6 hours ago
- NBC News
Cowboys owner Jerry Jones credits experimental drug after cancer diagnosis
OXNARD, Calif. — Dallas Cowboys owner Jerry Jones credited an experimental trial drug for successfully treating advanced melanoma as he disclosed his cancer diagnosis publicly for the first time. Jones revealed his illness in a documentary series, "America's Team: The Gambler and His Cowboys," which will debut on Netflix next week. The 82-year-old Jones then told The Dallas Morning News how he was initially diagnosed in June 2010 and underwent two surgeries on his lung and two on his lymph nodes over the next 10 years after skin cancer cells metastasized to other parts of his body. "Well, you don't like to think about your mortality, but I was so fortunate to have some great people that sent me in the right direction," Jones said after practice on Wednesday. "I got to be part of a trial that was propitious. It really worked. It's called PD-1 [therapy], and it really, really, really worked." First-year Cowboys coach Brian Schottenheimer described Jones' fight with cancer as an "amazing story" and praised him for going public. "I'm glad that Jerry shared it, just because I think it gives people hope," Schottenheimer said Wednesday. "It gives people the strength to say ... 'Hey, you can beat this.'" Schottenheimer, 51, used his last news conference of the Cowboys' nearly monthlong stay in Southern California to talk about his own cancer diagnosis. He underwent surgery in 2003 for thyroid cancer at the Mayo Clinic in Rochester, Minnesota. Then-Washington Commanders owner Dan Snyder helped arrange Schottenheimer's treatment two years after firing his father, Marty Schottenheimer, as coach. Brian Schottenheimer was Washington's quarterbacks coach during the 2001 season, the same year Snyder himself was treated for thyroid cancer. "It doesn't discriminate against anybody," Schottenheimer said. "And mine was certainly less serious, but I was 28 when I was diagnosed with thyroid cancer. Nothing like Stage 4, nothing like what Jerry and other people have to go through. But you hear that word 'cancer,' and it scares the hell out of you."
Fox Sports
9 hours ago
- Fox Sports
Cowboys Owner Jerry Jones Reveals Cancer Diagnosis, Credits Experimental Drug
National Football League Cowboys Owner Jerry Jones Reveals Cancer Diagnosis, Credits Experimental Drug Published Aug. 13, 2025 5:53 p.m. ET share facebook x reddit link Dallas Cowboys owner Jerry Jones credited an experimental trial drug for successfully treating advanced melanoma as he disclosed his cancer diagnosis publicly for the first time. Jones revealed his illness in a documentary, "America's Team: The Gambler and His Cowboys," which will debut on Netflix next week. The 82-year-old Jones then told The Dallas Morning News how he was initially diagnosed in June 2010 and underwent two surgeries on his lung and two on his lymph nodes over the next 10 years after skin cancer cells metastasized to other parts of his body. "I was saved by a fabulous treatment and great doctors and a real miracle (drug) called PD-1 (therapy)," Jones said. "I went into trials for that PD-1, and it has been one of the great medicines. I now have no tumors." First-year Cowboys head coach Brian Schottenheimer described Jones' fight with cancer as an "amazing story" and praised him for going public. "I'm glad that Jerry shared it, just because I think it gives people hope," Schottenheimer said Wednesday. "It gives people the strength to say, 'OK,' you know, 'Hey, you can beat this.'" ADVERTISEMENT Schottenheimer, 51, used his last news conference of the Cowboys' nearly monthlong stay in Southern California to talk about his own cancer diagnosis. He underwent surgery in 2003 for thyroid cancer at the Mayo Clinic in Rochester, Minnesota. Then-Washington Commanders owner Dan Snyder helped arrange Schottenheimer's treatment two years after firing his father, Marty Schottenheimer, as head coach. Brian Schottenheimer was Washington's quarterbacks coach during the 2001 season, the same year Snyder himself was treated for thyroid cancer. "It doesn't discriminate against anybody," Schottenheimer said. "And mine was certainly less serious, but I was 28 when I was diagnosed with thyroid cancer. Nothing like Stage 4, nothing like what Jerry and other people have to go through. But you hear that word 'cancer,' and it scares the hell out of you." Reporting by The Associated Press. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account, and follow leagues, teams and players to receive a personalized newsletter daily! FOLLOW Follow your favorites to personalize your FOX Sports experience National Football League Dallas Cowboys What did you think of this story? share
Yahoo
10 hours ago
- Yahoo
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating profit growth, resulting in a decline in its share price. The downgrade stems from weaker-than-expected momentum for its semaglutide-based obesity and diabetes drugs, Wegovy and Ozempic, especially in the U.S. obesity market. Despite the FDA ending its compounding grace period in May 2025, the company reported that illegal sales of counterfeit semaglutide persist under the pretext of personalization, hampering Wegovy's uptake. In response, the company is pursuing litigation and regulatory action to protect patients and market share. Wegovy's adoption has also been slower than anticipated in both cash and insured channels, despite efforts through NovoCare Pharmacy and telehealth partnerships. Market expansion has lagged, and competition in the GLP-1 obesity segment, especially from NVO's arch-rival, Eli Lilly LLY, has intensified. LLY markets its tirzepatide injections as Mounjaro for diabetes and Zepbound for obesity. Despite being on the market for a shorter duration, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Ozempic is also facing similar competitive pressures in the U.S. diabetes market, while international launches of Wegovy are experiencing uneven uptake across obesity markets. However, following a major pipeline setback for Eli Lilly, Novo Nordisk stock is staging a modest recovery, as is evident by the 5.8% gain in share price so far in August. Last week, LLY reported underwhelming efficacy results from the ATTAIN-1 study, the first of two pivotal phase III studies of its oral GLP-1 candidate, orforglipron, resulting in a significant drop in the stock price, given its strategic importance within Lilly's obesity pipeline. Investor sentiment was further dampened by the study's high patient discontinuation rates, stemming from both side effects and personal reasons, raising doubts about orforglipron's long-term utility in chronic obesity management. This presents a significant opportunity for Novo Nordisk to bounce back. NVO is making good progress with its pipeline, which includes several other new candidates for diabetes and obesity. The company also has strong fundamentals, and the untapped nature of the obesity market makes us believe that the stock has significant upside potential in the future. Let's dig deeper and understand the company's strengths and weaknesses to understand how to play the stock. Semaglutide – Still NVO's Primary Top-Line Driver Novo Nordisk's success in recent years has been driven by the sales of Ozempic (injection) and Rybelsus (oral) for diabetes, and Wegovy for obesity. Despite its recent market turmoil, the company holds a strong position in diabetes care, with one of the industry's broadest portfolios. Wegovy is a major revenue driver, recording sales of $5.41 billion (DKK 36.9 billion) during the first half of 2025, up 78% year over year on strong prescription growth. Ozempic also continues to boost overall revenues. To protect its lead amid competition from Lilly, Novo Nordisk is heavily investing in its GLP-1 manufacturing capacity. As of July 1, CVS Caremark, a major pharmacy benefit manager, has designated Wegovy as its preferred GLP-1 therapy for weight loss. Novo Nordisk is expanding semaglutide's reach through new indications. Wegovy is now approved for reducing major cardiovascular events, easing HFpEF symptoms, and relieving osteoarthritis-related knee pain in obesity. Ozempic's label includes use in diabetes patients with cardiovascular and kidney diseases. The FDA is reviewing Novo Nordisk's application for a 25 mg oral semaglutide for obesity, with a decision expected by year-end. Oral pills could boost adherence over injections. Potential approval would give Novo Nordisk a notable advantage as the sole manufacturer of a marketed oral obesity pill, positioning it to capture significant market share. NVO has also filed Rybelsus for cardiac event prevention in diabetes patients. A 7.2 mg Wegovy dose, showing up to 25% weight loss in the STEP UP study, is under EU review. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the EU. Beyond its GLP-1 portfolio, Novo Nordisk is broadening its presence in rare diseases. The company is advancing regulatory plans for Mim8 in hemophilia A and has secured EU approval for Alhemo to treat hemophilia A and B with inhibitors. Alhemo is also under EU review for patients without inhibitors. In the United States, the therapy is already approved for both hemophilia A and B, with or without inhibitors. It also expects to file for semaglutide to treat metabolic dysfunction–associated steatohepatitis in both the United States and the EU in 2025. NVO Focuses on Next-Generation Drugs for Obesity Novo Nordisk is also developing several next-generation obesity candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced weight loss candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. The company is planning its regulatory submission in 2026. Novo Nordisk is also developing a small-molecule oral CB1 inverse agonist, monlunabant, in a mid-stage study. The company is currently gearing up to advance Amycretin, an investigational unimolecular GLP-1 and amylin receptor agonist, for weight management into late-stage development. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, diabetes and other cardiometabolic diseases. Competition Heating Up in the Obesity Space Competition in the obesity market is heating up as the obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk presently dominate the market. Several other companies, like Amgen AMGN and Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and diabetes, with the first two phase III studies initiated in March. Viking Therapeutics started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. VKTX is also evaluating an oral version of this obesity drug in an ongoing mid-stage study, with a data readout expected later this year. NVO's Stock Price, Valuation, Estimates Year to date, Novo Nordisk shares have lost 42.1% compared with the industry's 8% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 12.12 forward earnings, which is lower than 13.73 for the industry. The stock is trading much below its five-year mean of 29.25. NVO Stock Valuation Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.86 to $3.89 per share over the past seven days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.20 to $4.24. NVO Estimate Movement Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 78.64%, which is higher than 34.32% for the large drugmaker industry, as seen in the chart below. NVO Return on Equity Image Source: Zacks Investment Research Here's How to Play NVO Stock Novo Nordisk, currently carrying a Zacks Rank #3 (Hold), remains a strong long-term player in diabetes and obesity care despite recent guidance cuts and competitive pressures. The company holds a dominant GLP-1 market position, with Wegovy and Ozempic delivering strong double-digit sales growth and benefiting from expanding indications. A potential FDA approval for 25 mg oral semaglutide for obesity by year-end could give NVO a first-to-market edge, improving adherence and broadening its reach. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Competition from Eli Lilly remains intense, but Lilly's recent setback with oral candidate orforglipron has pivoted investor sentiment toward NVO. The company's deep pipeline, including next-generation obesity candidates like CagriSema and Amycretin, along with rare disease therapies such as Mim8 and Alhemo, offers broad potential for market expansion. Manufacturing expansions and strategic deals, including a $2.2 billion Septerna partnership, also support long-term growth. Given these strengths, current holders may retain their positions, while long-term investors could use the current price as an entry point. Near-term volatility is likely due to competition, uneven Wegovy uptake internationally, and legal action over counterfeit semaglutide, making it less attractive for short-term trading. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
